| | 1942114-09-1 Basic information More.. |
| Product Name: | EAI-045 | | Synonyms: | EAI-045;2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide;EA1045;α-(5-fluoro-2-hydroxyphenyl)-1,3-dihydro-1-oxo-N-2-thiazolyl-2H-Isoindole-2-acetamide;EAI 045;EAI-045;CS-2350;EAI045;EAI 045;EAI-045;N-(3-((5-fluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (EAI-045) | | CAS: | 1942114-09-1 | | MF: | C19H14FN3O3S | | MW: | 383.4 | | EINECS: | | | Mol File: | 1942114-09-1.mol |  |
Use
EAI045 is a potent and selective EGFR inhibitor (fourth generation). EAI045 targets selected drug-resistant EGFR mutants without affecting the wild-type receptor. EAI045 inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays. Therefore, it is a potential candidate drug for the treatment of related non-small cell lung cancer (NSCLC). It should be noted that EAI-045 is effectively in targeting the EGFR C797S mutation, which is resistance to the third-generation EGFR inhibitors including AZD9291 (osimertinib) and CO-1686 (rociletinib).
- EAI-045
-
- US $9.80 / KG
- 2020-01-09
- CAS:1942114-09-1
- Min. Order: 1g
- Purity: ≥99%
- Supply Ability: 100kg
|
|
1942114-09-1
Recommend Suppliers |
|